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Batch Versus Flow Lithiation-Substitution of 1,3,4-Oxadiazoles: 
Exploitation of Unstable Intermediates Using Flow Chemistry 
Jeff Y. F. Wong, John M. Tobin, Filipe Vilela and Graeme Barker* 
Abstract: 1,3,4-Oxadiazoles are a common motif in pharmaceutical 
chemistry, but few convenient methods for their modification exist. A 
fast, convenient, high yielding and general α-substitution of 1,3,4-
oxadiazoles has been developed using a metalation-electrophilic 
trapping protocol both in batch and under continuous flow conditions 
in contradiction to previous reports which suggest that α-metalation of 
this ring system results in ring fragmentation. In batch, lithiation is 
accomplished at an industrially convenient temperature, –30 °C, with 
subsequent trapping giving isolated yields of up to 91%. Under 
continuous flow conditions, metalation is carried out at room 
temperature, and subsequent in flow electrophilic trapping gave up to 
quantitative isolated yields. Notably, lithiation in batch at room 
temperature results only in ring fragmentation and we propose that 
the superior mixing in flow allows interception and exploitation of an 
unstable intermediate before decomposition can occur. 
Introduction 
Oxadiazoles occupy an important role in modern medicinal 
chemistry,[1] often acting as bioisosteres of carboxylate 
derivatives including amides,[2] esters,[2] carbamates[3] and 
hydroxamic esters[4] as well as attracting attention for their 
optoelectronic properties.[5] In almost all cases the 1,3,4-isomer 
exhibits pharmacologically favorable activity with respect to 
lipophilicity (log D), hERG inhibition and metabolic stability.[1] 
Examples of bioactive 1,3,4-oxadiazoles include raltegravir with 
an antiretroviral activity[6] and zibotentan as an endothelin 
receptor antagonist[7] (figure 1). Often thought of as a  
Figure 1. Bioactive 1,3,4-oxadiazoles 
Scheme 1. Previous oxadiazole lithiations vs. this work 
 
comparatively delicate motif, oxadiazoles are typically installed 
late in target synthesis, and subsequent substitutions in adjacent 
positions analogous to isosteric α-amino acid-derived peptide 
stereocentres are correspondingly rare. 
 This paucity of oxadiazole modifications becomes 
problematic in light of the harsh conditions used to form the 
heterocycle, typically from a precursor hydrazide in DMSO or 
DMF at high temperature.[8] Therefore, there is a clear need to 
develop oxadiazole modifications in the heterobenzylic position. 
In this context, we herein disclose a convenient protocol for the α-
lithiation substitution of alkyl-1,3,4-oxadiazoles under both batch 
and continuous flow conditions using industrially accessible 
temperatures (–30 °C in batch and room temperature in flow),[9] 
short reaction times (1.3 s – 1 min) and a readily available non-
nucleophilic base, LDA. 
 Previous reports of alkyl-1,3,4-oxadiazole metalations are 
sparse, stemming from Micetich’s observation that attempted 
lithiation-trapping of 2,5-dimethyl-1,3,4-oxadiazole results solely 
in ring fragmentation (scheme 1).[10] While neither substrate nor 
trapped oxadiazoles were recovered, details of the ring 
fragmentation products were not given. Deaton has reported the 
α-lithiation of 2-methyl-5-aryl-1,3,4-oxadiazoles followed by 
trapping with aldehydes during the synthesis of cathepsin K 
inhibitors, however yields were modest, presumably due to 
competing ring fragmentation (scheme 1).[11] Katritzky has also 
reported the metalation of oxadiazolylmethyl-1H-benzotriazoles in 
the doubly benzylic position.[12] Ortho-metalation of aryl-1,3,4-
oxadiazoles to manganese[13] and iridium[14] metallacycles has 
been demonstrated, though subsequent C-C bond forming 
processes have not been reported. 
We have also optimised our new synthetic protocol for use 
under continuous flow conditions. Flow chemistry has enjoyed  
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Scheme 2. Previous in-flow deprotonations vs. this work 
 
considerable attention from synthetic chemists in recent years,[15] 
with multiple examples of group 1 and 2 organometallic reactions 
reported,[16] most notably by the groups of Knochel[17] and Ley.[18] 
However, formation of new organolithium species in flow has 
largely been restricted to halogen-lithium exchange or 
deprotonation at sp2 centres. Alezra[19] as well as Cantillo and 
Kappe[20] have separately reported LDA-mediated enolate 
formation under continuous flow conditions, and Ley reports the 
LiHMDS-facilitated heterobenzylic lithiation of methylpyridines.[21] 
While these examples detail the formation of chemically stable 
organolithiums usable under batch conditions, we herein report 
sp3 deprotonation to form an organolithium species which is 
unstable under comparable batch conditions. Subsequent in-flow 
interception by electrophilic trapping allows synthetic use of this 
intermediate and high yields of products could be obtained 
(scheme 2). 
 1,3,4-Oxadiazoles have previously been employed as 
amide and ester bioisosteres.[2] Commonly derived from amino 
acids, naturally occurring amide and ester protein ligands feature 
branching points at the α-position. We therefore proposed to 
investigate the possibility of substituting alkyl-1,3,4-oxadiazoles at 
the analogous carbon via a metalation-substitution approach. 
Results and Discussion 
We began our investigations by screening a number of different 
organolithium bases at –78 °C and the industrially accessible –
30 °C[9] for lithiation of oxadiazole 1 prior to electrophilic trapping 
with acetone (table 1). When deprotonating with nBuLi (entries 1 
and 2), modest conversions to 2 were observed with no remaining 
starting material due to competitive nucleophilic attack by nBuLi.1 
Switching to the more sterically hindered base sBuLi led to an 
increase in yields, providing 96% and 80% yields after 20 min at 
–78 °C and 1 min at –30 °C respectively (entries 3 and 4). We 
then investigated the milder and less  
                                                 
1 For further details, see ESI. 
 
Entry Base (1.3 eq.) Temp./°C Time Yield[a] 
1 nBuLi –78 1 h 44% 
2 nBuLi –30 15 min 48% 
3 sBuLi –78 20 min 96% 
4 sBuLi –30 1 min 80% 
5 LDA –78 20 min 92% 
6 
LDA –30 1 min 95% 
7 LDA rt 10 s 0% 
8 LDA rt 1.3 s 40% 
[a] as determined by 1H NMR in the presence of dimethylsulfone 
Table 1. Optimisation of oxadiazole modification 
  
nucleophilic base LDA: yields of 92% after 20 min at –78 °C and 
95% after 1 min at –30 °C were obtained.  Raising the 
temperature to rt resulted in decomposition of the lithiated 
intermediate after 10 s (entry 7) – inspection of the 1H NMR 
spectrum of the crude reaction mixture revealed a complex 
Scheme 3. Electrophile scope  
mixture of products (not including 1 or 2) which we were unable 
to separate, but which we propose arise from the ring 
fragmentation observed by Micetich.[10] Reducing the metalation  
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time to 1.3 s at rt gave a 40% yield of 2 with no remaining 1 (entry 
8), indicating that decomposition happens quickly after lithiation 
at room temperature. 
Having determined optimal metalation conditions, the wide 
electrophile scope was demonstrated. Good isolated yields were 
obtained after trapping with acetone, benzophenone, 
benzaldehyde, MeI, BnBr, Me2SO4, allyl bromide, and TMSBr 
(scheme 3). Attempted trapping with TMSCl gave only 51% of 
silylated product 8. Trapping with MeOD-d4 gave deuterated  
Scheme 4. β-Carbonyl derivative instability 
 
oxadiazole d-1 with 76% D incorporation. Attempts to trap with 
electrophiles to give β-carbonyloxadiazoles were less successful, 
with only a 24% isolated yield of amide 9 obtained after trapping  
with iPrNCO, and we were unable to isolate the expected products 
after trapping with BzCl, MeOCOCl or DMF. We propose that 
rather than inefficient trapping with these electrophiles, the 
products are unstable. Indeed, oxidation of a diastereopure 
sample of alcohol 4 (obtained from electrophilic trapping using 
PhCHO) with Dess-Martin periodinane led to initial formation of 
the expected ketone product (as observed by 1H NMR of the 
crude reaction mixture), which then decomposed to an 
unidentifiable complex mixture of products before purification 
could be carried out (scheme 4). Lithiation using 2.3 eq. LDA 
followed by 3.4 eq. MeOCOCl gave disubstituted product 10 in 
43% yield via interception of the unstable monosubstituted 
product by a second deprotonation-trapping event (scheme 4).   
Figure 2. X-ray structure of product 3. 
 An X-ray crystal structure of benzophenone trapped product 
3 indicated favorable hydrogen bonding between a β-hydroxyl 
substituent and the oxadiazole N3 position (figure 2). This 
observation led us to hypothesize that a decomposition pathway 
of β-carbonyloxadiazoles exists via formation of the enol tautomer.  
Indeed, when enol formation is disfavored (e.g.  in product 9) or 
impossible (10), β-carbonyl bearing products can be obtained.  
Scheme 5. Substrate scope.  
 Next, we turned our attention to the substrate scope 
(scheme 5) and began by investigating the effect of altering the 
alkyl chain undergoing metalation. Exchanging n-propyl for either 
ethyl (11) or n-octyl (12) chains maintained the efficiency of the 
reaction, with yields of 62% and 71% obtained respectively. We 
then probed functional group tolerance, and found that aryl (13, 
75% yield of trapped product), haloaryl (15, 81%), ether (16, 84%), 
trifluoromethyl (14, 74%), acetal (17, 91%) and dimethylamino (18, 
85%) motifs were pleasingly all compatible with the methodology. 
Di-N-Boc aminoalkyloxadiazole 22 also underwent efficient 
metalation, although in this case migration of a Boc group to give 
23 in 61% yield outcompeted trapping with an external 
electrophile. We then investigated the compatibility of a second 
oxadiazole substituent which could conceivably undergo 
metalation: phenylpropyloxadiazole underwent efficient 
substitution to give 19 in 71% yield with no evidence of aryl 
metalation observed. To our delight, when a second 
deprotonatable alkyl substituent is present, metalation trapping 
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occurs with complete selectivity at the less sterically hindered 
position, thought in these cases slightly higher yields were 
obtained using LiTMP rather than LDA (75% vs. 60% for 20 and 
79% vs. 55% for 21). No trace of product arising from metalation  
 
Figure 3. Lithiation of 1 followed by in situ 1H NMR 
 
at the other alkyl position was observed. 
 Next, we investigated attempting to optimize an 
enantioselective lithiation-substitution procedure. Unfortunately, 
after assaying a range of chiral lithium amide bases and a range  
of chiral diamine ligands in the presence of sBuLi, we were only 
able to obtain high yields of near racemic (best er = 55:45) 
products, and a “poor man’s Hoffman test” suggested that the 
lithiated intermediate might be configurationally unstable (see 
ESI).[22] Instead, we hypothesized that the lithiated intermediate 
24 may preferentially adopt its azaenolate form taut-24 in solution, 
precluding stereoselective substitution. To probe this, a sample of 
Figure 4. 1H NMR shifts of lithium enolates and lithium carbanions  
1 was metalated at –67 °C in THF-d8 and the reaction followed by 
1H NMR spectroscopy (figure 3).[23] Before addition of base, the 
heterobenzylic protons of 1 appear at δH 2.79 ppm. After addition  
of LDA, two signals are clearly visible at δH 2.79 and δH 2.75 ppm, 
corresponding to residual 1 and the alkenyl proton of azaenolate 
taut-24. While this may at first glance appear unusually upfield for 
an sp2 center proton, this does correspond to the spectrum for the 
analogous enolate of dimethylacetamide 25 as reported by 
Rathke (δH 3.16 and 2.93 ppm) and enolate 26 reported by Still 
(δH 3.50 ppm).[24] In contrast, the protons of C-lithated carbanions 
display considerably upfield shifts, with the benzylic protons of  
benzyllithium 27 at δH –0.77 ppm in THF-d8 and 2-lithioaziridines 
such as 28 in the range δH 1.20-0.90 ppm.[23a, 25] 
Next, we turned our attention to optimizing lithiation-
substitutions under continuous flow conditions. While we have 
shown that the reaction did not proceed in high yields at room 
temperature in batch due to decomposition of the lithiated 
intermediate (table 1, entries 7 and 8), we proposed that the 
superior mixing, heat transfer and control of reaction timing under 
continuous flow conditions would allow fast metalation then 
interception of the unstable intermediate with an electrophile 
before decomposition could take place. This is similar to the “flash 
chemistry” approach developed by Nagaki and Yoshida to 
intercept unstable reaction products or intermediates.[26] For 
example, ketone products may be obtained after treatment of 
acylchlorides with organolithiums without further reaction to the 
tertiary alcohol, and esters may be isolated after trapping 
organolithiums with Boc2O.[27] However, in–flow generation of 
unstable organolithium species has largely been limited to 
carbolithiation[28] and halogen-lithium exchange[29] processes; 
deprotonations are limited to a single example at an sp2 center,[30] 
or benzylic lithiations at low temperatures (≥–98 °C).[31] In this 
context, we have developed the first room temperature 
organolithium-mediated deprotonation to form an unstable  
 
Entry [1]/M tR1/s Yield[a] RSM[a] 
1 0.39 5.6 39% 24% 
2 0.39 14.0 41% 22% 
3 0.39 28 34% 16% 
4 0.23 28 45% 0% 
5 0.23 2.8 86% 0% 
[a] as determined by 1H NMR in the presence of dimethylsulfone 
Table 2. Optimisation of continuous flow metalation. 
 
intermediate followed by fast in-flow trapping before 
decomposition can take place as it would under batch conditions.
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 We began by investigating the effect of metalating 
oxadiazole 1 with LDA under continuous flow conditions at rt and 
pumping the resulting solution into a flask containing a rapidly 
stirring solution of benzophenone in THF at rt (table 2). Reactor 
residence time (tR1) for the metalation step was varied by 
changing the flow rate. When utilizing a 0.39 M solution of 
oxadiazole 1 in THF (analogous stoichiometry to our optimized 
batch conditions), a significant amount of starting material was 
recovered, even after extended reactor residence times (entries 
1-3). For example, after tR1 = 28 s, only a 34% yield of 3 was 
obtained, with 16% 1 remaining. Inspection of the 1H NMR 
spectrum of the crude product revealed that the significant mass 
loss was due to competitive ring fragmentation. Reduction of the 
Scheme 6. Oxadiazole lithiation-substitution in flow  
concentration of the 1 feedstock solution was able to remedy this 
problem, with a 45% yield of 3 obtained with no remaining 1 after 
tR1 = 28 s (entry 4). Reducing the residency time to 2.8 s greatly 
reduced ring fragmentation, and an 86% yield of 3 was obtained 
with no remaining 1 (entry 5).  
With high-yielding continuous flow metalation conditions in 
hand, we decided to investigate subsequent in-flow electrophilic 
trapping. To our delight, metalation of oxadiazole 1 with LDA in 
THF at rt with a reactor residence time (tR1) of 1.3 s followed by 
trapping with acetone (tR2 = 2.8 s) afforded product 2 in 82% yield, 
comparable with the batch yield of 86% (scheme 6). A selection 
of oxadiazoles and electrophiles was then chosen to demonstrate 
the scope of the reaction under continuous flow conditions 
(scheme 6) and in each case yields were comparable to the 
equivalent batch synthesis at –30 °C. Notably, acetal-containing 
oxadiazole 18 was obtained in quantitative yields. As an exception 
to this rule, we found that when flow metalation-trapping was 
attempted with a slowly reacting electrophile, TMSBr, only a trace 
amount of product 8 was obtained. 
Scheme 7. Large scale flow lithiation-substitution  
We also wished to demonstrate the utility of our flow 
protocol on a larger scale and determine the productivity rate 
(scheme 7). Thus, under our standard continuous flow conditions, 
12.5 mmol of oxadiazole 1 was metalated and trapped over 5 min 
to give an 85% yield of 2. This corresponds to a productivity rate 
of 28.8 g/h, or alternatively 7.9 h would be required to produce a 
mole of product. 
 Finally, we wished to demonstrate the utility of the in-flow 
lithiation-substitution with a formal synthesis of a sub-nanomolar 
cathepsin K inhibitor developed to combat osteoporosis.[11] Thus, 
oxadiazole 25 was subjected to our standard in-flow metalation 
conditions before in-flow trapping with pivaldehyde to give key 
inhibitor synthetic intermediate 26 in 95% yield (scheme 8).  
Scheme 8. Formal synthesis of a cathepsin K inhibitor 
Conclusions 
In conclusion, we have developed a fast and convenient lithiation-
substitution protocol for alkyl-1,3,4-oxadiazoles and 
demonstrated its utility with a wide range of substrates and 
electrophiles both in batch and under continuous flow conditions. 
Our approach addresses key limitations of previous attempts to 
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effect oxadiazole metalation, namely competitive decomposition 
of the metalated intermediate and extremely limited substrate and 
electrophile scope. In batch, our conditions (–30 °C for 1 min then 
electrophilic trapping) are amenable for use on a process scale 
and gave up to 91% isolated yields, while under flow conditions 
room temperature may be used, giving up to quantitative yields. 
The success of our approach rested on the use of a non-
nucleophilic lithium amide base (LDA or LiTMP) and either cooling 
to –30 °C in batch or the use of a fast deprotonation-trapping 
strategy in flow to avoid decomposition of reaction intermediates. 
Experimental Section 
Typical procedures for batch and flow lithiation-substitutions of an 
alkyl-1,3,4-oxadiazole are given below. For full details and all data, 
see SI. 
General Lithiation-Substitution Procedure in Batch: 
LDA (1.3 eq.) was added dropwise to a stirred solution of 
oxadiazole (1.0 eq.) in THF at –30 °C. The resulting solution was 
stirred at –30 °C for 1 min then electrophile (2.0 eq.) was added. 
The resulting solution was stirred at –30 °C for 10 min then 
allowed to warm to rt over 16 h. Saturated NH4Cl(aq) solution was 
added and the layers separated, extracting the aqueous with Et2O 
(×3). The combined organic layers were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product. 
General Lithiation-Substitution Procedure in Continuous 
Flow: 
All continuous flow reactions were carried out using the easy-
Photochem flow reactor from Vapourtec Ltd. A 0.25 M solution of 
oxadiazole in THF and a 0.5 M solution of LDA in THF were driven 
through two separate peristaltic pumps at 10 mLmin–1 at rt. The 
solutions were pumped through 1 mm I.D. PTFE tubing and mixed 
at a T-junction. The resulting solution was passed through a 
length of tubing (10 mLmin–1, 0.28 mL, tR1 = 1.3 s) before mixing 
at a second T-junction with a 1.0 M solution of electrophile 
pumped at 10 mLmin–1 through a third peristaltic pump. The 
resulting solution was passed through  a second length of tubing 
(10 mLmin–1, 0.47 mL, tR2 = 2.8 s) and collected as the product 
solution. After the flow had reached a steady state, the product 
solution was collected for 15 s. A saturated solution of NH4Cl(aq) 
was added to the collected product solution and the layers were 
separated, extracting the aqueous with Et2O (×3). The combined 
organic layers were dried (MgSO4) and evaporated under 
reduced pressure to give the crude product. 
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